Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1998-11-17
2000-05-02
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514665, A61K 3156, A61K 3113
Patent
active
060573082
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a pharmaceutical reparation for treating or preventing hyperlipemia.
BACKGROUND ART
Blood lipid components such as cholesterols, neutral fats, phospholipids or free fatty acids are in the form of water-soluble lipoproteins in the blood, which are classified into very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) by the difference of density. Hyperlipemia is in a status of higher blood concentration of these lipid components which is caused by abnormal lipoprotein metabolism in the body than the normal concentration. When the status of hyperlipemia is continued for a long term, cholesterol and the like tend to deposit into the artery wall, and it has been found by many investigations and epidemiological research that atherosclerosis such as myocardial infarction, angina pectoris or cerebral infarction originates and develops. Accordingly, it is important to lower the blood concentration of these lipid components to the normal concentration for treating hyperlipemia, and it is important to maintein the normal concentration for preventing hyperlipemia.
Taurine (aminoethylsulfonic acid) is a sulfur-containing amino acid having a very simple chemical structure with a molecular weight of 125.14, and known to have various pharmacological properties, over a broad area beginning with central nervous system, circulatory system and hepatobiliary system. Concerning the properties of taurine to the cholesterol metabolism, there are also known the lowering effect of serum cholesterol via cholagogic function and inhibition of gallstone formation by cholesterol.
.gamma.-Oryzanol is known to have the properties to inhibit the absorption of cholesterol and improve the lipoprotein metabolism.
For treating hyperlipemia at the present time, dietetic therapy is first applied, and when it is not sufficiently effective, drug theraphy needs to be applied.
Recently, there are some pharmaceutical drugs of hyperlipemia with different mechanism of action (absorption inhibition, excretion acceleration and synthesis inhibition), but they have a problem of the side-effects, main examples of which are leukocyte decrease, hepatic enlargement, gastrointestinal troubles, sexuality reduction, etc. Accordingly, a pharmaceutical drug for treating or preventing hyperlipemia without side-effects is desirable.
In view of preventive medicine, a desired drug for preventing the origination of hyperlipemia is one which maintains the low blood concentration of lipid components (e.g. cholesterols, neutral fats, phospholipids and free fatty acids), has no side-effect, and can be administered safely for a long term.
An object of the present invention is to provide a pharmaceutical preparation of treating or preventing hyperlipemia which is safe even if applied for a long term.
DISCLOSURE OF THE INVENTION
The present inventors have found that an administration of taurine and .gamma.-oryzanol at the same time has a greater effect to improve the metabolism of excess amount of lipid components in the body such as cholesterol than an administration of either taurine or .gamma.-oryzanol alone, and have accomplished the present invention by the finding.
Accordingly, the present invention relates to a pharmaceutical preparation for treating or preventing hyperlipemia comprising taurine and .gamma.-oryzanol as effective components.
The pharmaceutical preparation for treating or preventing hyperlipemia of the present invention lowers the blood concentration of excess amount of lipid components in the body (e.g. cholesterols, neutral fats, phospholipids and free fatty acids), and has a property to improve lipoprotein metabolism, thereby it is useful as a pharmaceutical preparation for treating or preventing hyperlipemia, especially, it is very useful as a pharmaceutial preparation for preventing hyperlipemia because it has no side-effect and can be administered safely for a long term.
According to the present invention, the effective dose of taurine is from 100
REFERENCES:
CA 120:297323, Venkatesan et al., 1993.
CA 118:622, Ito et al., 1992.
Kitajima Hideaki
Murakami Shigeru
Tsunoda Kenji
Yanagita Teruyoshi
Jordan Kimberly
Taisho Pharmaceutical Co. Ltd.
LandOfFree
Remedy or preventive for hyperlipemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedy or preventive for hyperlipemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedy or preventive for hyperlipemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1593937